<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36995412</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1420-908X</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Inflammation research : official journal of the European Histamine Research Society ... [et al.]</Title><ISOAbbreviation>Inflamm Res</ISOAbbreviation></Journal><ArticleTitle>Long-COVID fatigue is not predicted by pre-pandemic plasma IL-6 levels in mild COVID-19.</ArticleTitle><Pagination><StartPage>947</StartPage><EndPage>953</EndPage><MedlinePgn>947-953</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00011-023-01722-2</ELocationID><Abstract><AbstractText Label="OBJECTIVE AND DESIGN" NlmCategory="OBJECTIVE">Fatigue is a prominent symptom in the general population and may follow viral infection, including SARS-CoV2 infection which causes COVID-19. Chronic fatigue lasting more than three months is the major symptom of the post-COVID syndrome (known colloquially as long-COVID). The mechanisms underlying long-COVID fatigue are unknown. We hypothesized that the development of long-COVID chronic fatigue is driven by the pro-inflammatory immune status of an individual prior to COVID-19.</AbstractText><AbstractText Label="SUBJECTS AND METHODS" NlmCategory="METHODS">We analyzed pre-pandemic plasma levels of IL-6, which plays a key role in persistent fatigue, in N&#x2009;=&#x2009;1274 community dwelling adults from TwinsUK. Subsequent COVID-19-positive and -negative participants were categorized based on SARS-CoV-2 antigen and antibody testing. Chronic fatigue was assessed using the Chalder Fatigue Scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">COVID-19-positive participants exhibited mild disease. Chronic fatigue was a prevalent symptom among this population and significantly higher in positive vs. negative participants (17% vs 11%, respectively; p&#x2009;=&#x2009;0.001). The qualitative nature of chronic fatigue as determined by individual questionnaire responses was similar in positive and negative participants. Pre-pandemic plasma IL-6 levels were positively associated with chronic fatigue in negative, but not positive individuals. Raised BMI was associated with chronic fatigue in positive participants.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Pre-existing increased IL-6 levels may contribute to chronic fatigue symptoms, but there was no increased risk in individuals with mild COVID-19 compared with uninfected individuals. Elevated BMI also increased the risk of chronic fatigue in mild COVID-19, consistent with previous reports.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Freidin</LastName><ForeName>Maxim B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Twin Research and Genetic Epidemiology, School of Life Course and Population Sciences, King's College London, London, UK. maxim.freydin@kcl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, School of Biological and Behavioural Sciences, Queen Mary University of London, London, UK. maxim.freydin@kcl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheetham</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Twin Research and Genetic Epidemiology, School of Life Course and Population Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duncan</LastName><ForeName>Emma L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Twin Research and Genetic Epidemiology, School of Life Course and Population Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steves</LastName><ForeName>Claire J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Twin Research and Genetic Epidemiology, School of Life Course and Population Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doores</LastName><ForeName>Katherine J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, School of Immunology &amp; Microbial Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malim</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, School of Immunology &amp; Microbial Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Niccolo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Twin Research and Genetic Epidemiology, School of Life Course and Population Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lord</LastName><ForeName>Janet M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Birmingham Biomedical Research Centre, University Hospital Birmingham and University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franks</LastName><ForeName>Paul W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Lund University Diabetes Center, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Sciences, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borsini</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granville Smith</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Twin Research and Genetic Epidemiology, School of Life Course and Population Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falchi</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Twin Research and Genetic Epidemiology, School of Life Course and Population Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pariante</LastName><ForeName>Carmine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Frances M K</ForeName><Initials>FMK</Initials><AffiliationInfo><Affiliation>Department of Twin Research and Genetic Epidemiology, School of Life Course and Population Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G108/603</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/J002739/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N029488/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/T004142/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Inflamm Res</MedlineTA><NlmUniqueID>9508160</NlmUniqueID><ISSNLinking>1023-3830</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BMI</Keyword><Keyword MajorTopicYN="N">Chronic fatigue</Keyword><Keyword MajorTopicYN="N">IL-6</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword></KeywordList><CoiStatement>Authors declare no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36995412</ArticleId><ArticleId IdType="pmc">PMC10062244</ArticleId><ArticleId IdType="doi">10.1007/s00011-023-01722-2</ArticleId><ArticleId IdType="pii">10.1007/s00011-023-01722-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS&#xa0;One. 2020;15(11):e0240784. doi: 10.1371/journal.pone.0240784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240784</ArticleId><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Grygiel-Gorniak B, Puszczewicz M. Fatigue and interleukin-6 - a multi-faceted relationship. Reumatologia. 2015;53(4):207&#x2013;212. doi: 10.5114/reum.2015.53998.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/reum.2015.53998</ArticleId><ArticleId IdType="pmc">PMC4847294</ArticleId><ArticleId IdType="pubmed">27407249</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolak A, Kami&#x144;ska M, Wysoki&#x144;ska E, Surdyka D, Kieszko D, Pakie&#x142;a M, et al. The problem of fatigue in patients suffering from neoplastic disease. Contemp Oncol (Pozn) 2017;21(2):131&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5611502</ArticleId><ArticleId IdType="pubmed">28947882</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelnovo L, Tamburello A, Lurati A, Zaccara E, Marrazza MG, Olivetti M, et al. Anti-IL6 treatment of serious COVID-19 disease: a monocentric retrospective experience. Medicine (Baltimore) 2021;100(1):e23582. doi: 10.1097/MD.0000000000023582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000023582</ArticleId><ArticleId IdType="pmc">PMC7793456</ArticleId><ArticleId IdType="pubmed">33429732</ArticleId></ArticleIdList></Reference><Reference><Citation>Abidi E, El Nekidy WS, Alefishat E, Rahman N, Petroianu GA, El-Lababidi R, et al. Tocilizumab and COVID-19: timing of administration and efficacy. Front Pharmacol. 2022;13:825749. doi: 10.3389/fphar.2022.825749.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.825749</ArticleId><ArticleId IdType="pmc">PMC8894855</ArticleId><ArticleId IdType="pubmed">35250575</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappelmann N, Dantzer R, Khandaker GM. Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology. 2021;131:105295. doi: 10.1016/j.psyneuen.2021.105295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2021.105295</ArticleId><ArticleId IdType="pmc">PMC8172271</ArticleId><ArticleId IdType="pubmed">34119855</ArticleId></ArticleIdList></Reference><Reference><Citation>Milaneschi Y, Kappelmann N, Ye Z, Lamers F, Moser S, Jones PB, et al. Association of inflammation with depression and anxiety: evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts. Mol Psychiatry. 2021;26:7393&#x2013;7402. doi: 10.1038/s41380-021-01188-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01188-w</ArticleId><ArticleId IdType="pmc">PMC8873022</ArticleId><ArticleId IdType="pubmed">34135474</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell A, Hepgul N, Nikkheslat N, Borsini A, Zajkowska Z, Moll N, et al. Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome. Psychoneuroendocrinology. 2019;100:276&#x2013;285. doi: 10.1016/j.psyneuen.2018.11.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2018.11.032</ArticleId><ArticleId IdType="pmc">PMC6350004</ArticleId><ArticleId IdType="pubmed">30567628</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl 1):S4&#x2013;9. doi: 10.1093/gerona/glu057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glu057</ArticleId><ArticleId IdType="pubmed">24833586</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett DB, Firth CM, Phillips AC, Moss P, Baylis D, Syddall H, et al. The age-related increase in low-grade systemic inflammation (Inflammaging) is not driven by cytomegalovirus infection. Aging Cell. 2012;11(5):912&#x2013;915. doi: 10.1111/j.1474-9726.2012.00849.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2012.00849.x</ArticleId><ArticleId IdType="pubmed">22708923</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew T, Hart DJ, Snieder H, de Lange M, Spector TD, MacGregor AJ. Are twins and singletons comparable? A study of disease-related and lifestyle characteristics in adult women. Twin Res. 2001;4(6):464&#x2013;477. doi: 10.1375/twin.4.6.464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1375/twin.4.6.464</ArticleId><ArticleId IdType="pubmed">11780939</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdi S, Abbasian G, Bowyer RCE, Lachance G, Yarand D, Christofidou P, et al. TwinsUK: the UK adult twin registry update. Twin Res Hum Genet. 2019;22(6):523&#x2013;529. doi: 10.1017/thg.2019.65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/thg.2019.65</ArticleId><ArticleId IdType="pubmed">31526404</ArticleId></ArticleIdList></Reference><Reference><Citation>Suthahar A, Sharma P, Hart D, Garc&#xed;a MP, Horsfall R, Bowyer RCE, et al. TwinsUK COVID-19 personal experience questionnaire (CoPE): wave 1 data capture April-May 2020. Wellcome Open Res. 2021;6:123. doi: 10.12688/wellcomeopenres.16671.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.16671.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Muench P, Jochum S, Wenderoth V, Ofenloch-Haehnle B, Hombach M, Strobl M, et al. Development and validation of the Elecsys Anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2. J Clin Microbiol. 2020;58(10):e01694&#x2013;e1720. doi: 10.1128/JCM.01694-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01694-20</ArticleId><ArticleId IdType="pmc">PMC7512151</ArticleId><ArticleId IdType="pubmed">32747400</ArticleId></ArticleIdList></Reference><Reference><Citation>Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598&#x2013;1607. doi: 10.1038/s41564-020-00813-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-00813-8</ArticleId><ArticleId IdType="pmc">PMC7610833</ArticleId><ArticleId IdType="pubmed">33106674</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C. The Chalder fatigue scale (CFQ 11) Occup Med (Lond) 2015;65(1):86. doi: 10.1093/occmed/kqu168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/occmed/kqu168</ArticleId><ArticleId IdType="pubmed">25559796</ArticleId></ArticleIdList></Reference><Reference><Citation>Cella M, Chalder T. Measuring fatigue in clinical and community settings. J Psychosom Res. 2010;69(1):17&#x2013;22. doi: 10.1016/j.jpsychores.2009.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2009.10.007</ArticleId><ArticleId IdType="pubmed">20630259</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho HJ, Kivimaki M, Bower JE, Irwin MR. Association of C-reactive protein and interleukin-6 with new-onset fatigue in the Whitehall II prospective cohort study. Psychol Med. 2013;43(8):1773&#x2013;1783. doi: 10.1017/S0033291712002437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291712002437</ArticleId><ArticleId IdType="pmc">PMC3819455</ArticleId><ArticleId IdType="pubmed">23151405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575. doi: 10.1136/bmj.38933.585764.AE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.38933.585764.AE</ArticleId><ArticleId IdType="pmc">PMC1569956</ArticleId><ArticleId IdType="pubmed">16950834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim W, Hong S, Nelesen R, Dimsdale JE. The association of obesity, cytokine levels, and depressive symptoms with diverse measures of fatigue in healthy subjects. Arch Intern Med. 2005;165(8):910&#x2013;915. doi: 10.1001/archinte.165.8.910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.165.8.910</ArticleId><ArticleId IdType="pubmed">15851643</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83(3):847&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pubmed">9506738</ArticleId></ArticleIdList></Reference><Reference><Citation>Collin SM, Nikolaus S, Heron J, Knoop H, White PD, Crawley E. Chronic fatigue syndrome (CFS) symptom-based phenotypes in two clinical cohorts of adult patients in the UK and The Netherlands. J Psychosom Res. 2016;81:14&#x2013;23. doi: 10.1016/j.jpsychores.2015.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2015.12.006</ArticleId><ArticleId IdType="pubmed">26800634</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>